ArticleKidney international reports2025
Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Treatment of Autosomal Dominant Polycystic Kidney Disease: Integrating Clinical Practice Guidelines, Patient Perspectives, and Real-World Effectiveness.Journal of the American Society of Nephrology : JASN · 2026Review
- Machine learning for predicting CKD stages in patients with autosomal dominant polycystic kidney disease: a nationwide cohort study in Japan.Scientific reports · 2026Article
- Trajectories of Kidney Function in Autosomal Dominant Polycystic Kidney Disease Patients Treated with Tolvaptan.Medicina (Kaunas, Lithuania) · 2026Article
- Cardiovascular Complications in ADPKD.Kidney international reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In Japan, the therapeutic dose of tolvaptan (60-120 mg/d) must be discontinued at chronic kidney disease stage G5 (CKD-G5), eGFR < 15 ml/min per 1.73 m Methods: This was a Japanese nation-wide, multicenter, retrospective observational study. Between May 2014 and September 2019, 110 patients with ADPKD developed CKD-G5 were included (data: previous 10 years). Participants were categorized into 3 groups: the tolvaptan continued group (received tolvaptan before CKD-G5 and reduced the dose to ≤ 15 mg at CKD-G5, Results: The eGFR slope remained stable before and during CKD-G5 in the non-tolvaptan group. In the tolvaptan discontinued group, the eGFR slope was accelerated from before (-3.3 [-4.3, -2.5] ml/min per 1.73 m Conclusion: Continuation of low-dose tolvaptan may be effective in suppressing kidney function deterioration in ADPKD patients with CKD-G5. A clinical trial is needed to evaluate its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.